![Re-irradiation in treating recurrent head and neck cancer](https://oncodaily.com/pub/uploads/2024/06/allen_chen_allenmc2_0.png)
Re-irradiation in treating recurrent head and neck cancer
Aren Karapetyan, Resident at Yerevan State Medical University named after Mkhitar Heratsi, shared a paper by Allen Chen et al. titled “Re-irradiation versus systemic therapy for the management of local-regionally recurrent head and neck cancer” published in Radiotherapy and Oncology.
Authors: Allen Chen, Jeremy Harris, Rupali Nabar, Tjoson Tjoa, Yarah Haidar, William Armstrong.
Aren Karapetyan commented on X sharing the paper:
“The benefits of re-irradiation versus systemic therapy in treating recurrent head and neck cancer.
Research shows re-irradiation significantly improves 2-year overall survival (32% vs. 11%) and progression-free survival (31% vs. 7%), as well as local-regional control (39% vs. 3%).
However, it also poses a higher risk of new grade 3+ toxicities (53% vs. 28%) and late toxicities (48% vs. 12%) compared to systemic therapy alone.”
Source: Aren Karapetyan/X
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023